Top

Published in:

01-06-2011

Antifungal Therapy in Pediatric Patients

Authors: Thomas Lehrnbecher, Konrad Bochennek, Dominik Schrey, Andreas H. Groll

Published in: Current Fungal Infection Reports | Issue 2/2011

Abstract

Invasive fungal infections still play a major role in morbidity and mortality in pediatric patients, especially in children undergoing therapy for an underlying malignancy and in preterm infants. Relative to the adult population, pediatric age groups display important differences not only in host biology, predisposing conditions, epidemiology, and presentation of fungal infections, but also in the disposition and clearance of antifungal compounds. During the past decade, several new antifungal agents have been developed. Although not all of these agents are yet approved for children, the pediatric development of antifungal agents has moved forward in an exemplary manner, which is essential for the successful management of the individual patient. This article reviews the current data on pharmacokinetics, safety, and dosing of antifungal agents in pediatric patients.

Nath CE, Shaw PJ, Gunning R, et al. Amphotericin B in children with malignant disease: a comparison of the toxicities and pharmacokinetics of amphotericin B administered in dextrose versus lipid emulsion. Antimicrob Agents Chemother. 1999;43:1417–23.PubMed

Kingo AR, Smyth JA, Waisman D. Lack of evidence of amphotericin B toxicity in very low birth weight infants treated for systemic candidiasis. Pediatr Infect Dis J. 1997;16:1002–3.PubMedCrossRef

Le J, Adler-Shohet FC, Nguyen C, Lieberman JM. Nephrotoxicity associated with amphotericin B deoxycholate in neonates. Pediatr Infect Dis J. 2009;28:1061–3.PubMedCrossRef

Groll AH, Piscitelly TJ, Walsh TJ. Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv Pharmacol. 1998;44:343–500.PubMedCrossRef

Adler-Moore JP, Proffitt RT. Amphotericin B lipid preparations: what are the differences? Clin Microbiol Infect. 2008;14 Suppl 4:25–36.PubMedCrossRef

Amantea MA, Bowden RA, Forrest A, et al. Population pharmacokinetics and renal function-sparing effects of amphotericin B colloidal dispersion in patients receiving bone marrow transplants. Antimicrob Agents Chemother. 1995;39:2042–7.PubMed

Sandler ES, Mustafa MM, Tkaczewski I, et al. Use of amphotericin B colloidal dispersion in children. J Pediatr Hematol Oncol. 2000;22:242–6.PubMedCrossRef

Walsh TJ, Whitcomb P, Piscitelli S, et al. Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis. Antimicrob Agents Chemother. 1997;41:1944–8.PubMed

Adedoyin A, Bernardo JF, Swenson CE, et al. Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): combined experience from phase I and phase II studies. Antimicrob Agents Chemother. 1997;41:2201–8.PubMed

10.

Wurthwein G, Groll AH, Hempel G, et al. Population pharmacokinetics of amphotericin B lipid complex in neonates. Antimicrob Agents Chemother. 2005;49:5092–8.PubMedCrossRef

11.

Wiley JM, Seibel NL, Walsh TJ. Efficacy and safety of amphotericin B lipid complex in 548 children and adolescents with invasive fungal infections. Pediatr Infect Dis J. 2005;24:167–74.PubMedCrossRef

12.

Walsh TJ, Seibel NL, Arndt C, et al. Amphotericin B lipid complex in pediatric patients with invasive fungal infections. Pediatr Infect Dis J. 1999;18:702–8.PubMedCrossRef

13.

Walsh T, Shad A, Bekersky I, et al. Safety, tolerability and pharmacokinetics of liposomal amphotericin B in immunocompromised pediatric patients [abstract], 2008. Presented at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC; October 25–28, 2008: A-005.

14.

Walsh TJ, Yeldandi V, McEvoy M, et al. Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients. Antimicrob Agents Chemother. 1998;42:2391–8.PubMed

15.

Hong Y, Shaw PJ, Nath CE, et al. Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases. Antimicrob Agents Chemother. 2006;50:935–42.PubMedCrossRef

16.

Prentice HG, Hann IM, Herbrecht R, et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol. 1997;98:711–8.PubMedCrossRef

17.

Scarcella A, Pasquariello MB, Giugliano B, et al. Liposomal amphotericin B treatment for neonatal fungal infections. Pediatr Infect Dis J. 1998;17:146–8.PubMedCrossRef

18.

Groll AH, Ritter J. Diagnosis and management of fungal infections and pneumocystis pneumonitis in pediatric cancer patients. Klin Pädiatr. 2005;217 Suppl 1:S37–66.PubMedCrossRef

19.

Wade KC, Wu D, Kaufman DA, et al. Population pharmacokinetics of fluconazole in young infants. Antimicrob Agents Chemother. 2008;52:4043–9.PubMedCrossRef

20.

• Wade KC, Benjamin Jr DK, Kaufman DA, et al. Fluconazole dosing for the prevention or treatment of invasive candidiasis in young infants. Pediatr Infect Dis J. 2009;28:717–23. This important, population-based pharmacokinetic study led to changes in dosing of fluconazole in neonates and young infants.PubMedCrossRef

21.

Novelli V, Holzel H. Safety and tolerability of fluconazole in children. Antimicrob Agents Chemother. 1999;43:1955–60.PubMed

22.

Kaufman D, Boyle R, Hazen KC, et al. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med. 2001;345:1660–6.PubMedCrossRef

23.

Manzoni P, Stolfi I, Pugni L, et al. A multicenter, randomized trial of prophylactic fluconazole in preterm neonates. N Engl J Med. 2007;356:2483–95.PubMedCrossRef

24.

Groll AH, Wood L, Roden M, et al. Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis. Antimicrob Agents Chemother. 2002;46:2554–63.PubMedCrossRef

25.

Hennig S, Wainwright CE, Bell SC, et al. Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients. Clin Pharmacokinet. 2006;45:1099–114.PubMedCrossRef

26.

Abdel-Rahman SM, Jacobs RF, Massarella J, et al. Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents. Antimicrob Agents Chemother. 2007;51:2668–73.PubMedCrossRef

27.

Baley JE, Meyers C, Kliegman RM, et al. Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates. J Pediatr. 1990;116:791–7.PubMedCrossRef

28.

Pasqualotto AC, Howard SJ, Moore CB, Denning DW. Flucytosine therapeutic monitoring: 15 years experience from the UK. J Antimicrob Chemother. 2007;59:791–3.PubMedCrossRef

29.

Francis P, Walsh T. Evolving role of flucytosine in immunocompomied patients: new insights into safety, pharmacokinetic, and antifungal therapy. Clin Infect Dis. 1992;15:1003–18.PubMedCrossRef

30.

Walsh TJ, Karlsson MO, Driscoll T, et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother. 2004;48:2166–72.PubMedCrossRef

31.

Yanni SB, Annaert PP, Augustijns P, et al. In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3. Drug Metab Dispos. 2010;38:25–31.PubMedCrossRef

32.

Karlsson MO, Lutsar I, Milligan PA. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob Agents Chemother. 2009;53:935–44.PubMedCrossRef

33.

Neely M, Rushing T, Kovacs A, et al. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin Infect Dis. 2010;50:27–36.PubMedCrossRef

34.

Shima H, Miharu M, Osumi T, et al. Differences in voriconazole trough plasma concentrations per oral dosages between children younger and older than 3 years of age. Pediatr Blood Cancer. 2010;54:1050–2.PubMed

35.

Walsh TJ, Lutsar I, Driscoll T, et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J. 2002;21:240–8.PubMedCrossRef

36.

Cowen EW, Nguyen JC, Miller DD, et al. Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole. J Am Acad Dermatol. 2010;62:31–7.PubMedCrossRef

37.

Krishna G, Sansone-Parsons A, Martinho M, et al. Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. Antimicrob Agents Chemother. 2007;51:812–8.PubMedCrossRef

38.

Lehrnbecher T, Attarbaschi A, Duerken M, et al. Posaconazole salvage treatment in paediatric patients: a multicentre survey. Eur J Clin Microbiol Infect Dis. 2010;29:1043–5.PubMedCrossRef

39.

Benjamin Jr DK, Driscoll T, Seibel NL, et al. Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob Agents Chemother. 2006;50:632–8.PubMedCrossRef

40.

Vazquez JA, Sobel JD. Anidulafungin: a novel echinocandin. Clin Infect Dis. 2006;43:215–22.PubMedCrossRef

41.

Walsh TJ, Adamson PC, Seibel NL, et al. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother. 2005;49:4536–45.PubMedCrossRef

42.

Neely M, Jafri HS, Seibel N, et al. Pharmacokinetics and safety of caspofungin in older infants and toddlers. Antimicrob Agents Chemother. 2009;53:1450–6.PubMedCrossRef

43.

Li C, Sun P, Dong Y, et al. Population pharmacokinetics and pharmacodynamics of caspofungin in pediatric patients [abstract]. Presented at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC; October 25–28, 2008: A-006.

44.

Saez-Llorens X, Macias M, Maiya P, et al. Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age. Antimicrob Agents Chemother. 2009;53:869–75.PubMedCrossRef

45.

Zaoutis T, Lehrnbecher T, Groll AH, et al. Safety experience with caspofungin in pediatric patients. Pediatr Infect Dis J. 2009;28:1132–5.PubMedCrossRef

46.

• Maertens JA, Madero L, Reilly AF, et al. A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia. Pediatr Infect Dis J. 2010;29:415–20. This randomized, multicenter study demonstrates that caspofungin and liposomal amphotericin B are comparable in tolerability, safety, and efficacy as empiric antifungal therapy for persistently febrile, neutropenic pediatric patients.PubMedCrossRef

47.

Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med. 2004;351:1391–402.PubMedCrossRef

48.

Groll AH, Stergiopoulou T, Roilides E, Walsh T. Micafungin: pharmacology, experimental therapeutics and clinical applications. Expert Opin Investig Drugs. 2005;14:489–509.PubMedCrossRef

49.

Seibel NL, Schwartz C, Arrieta A, et al. Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother. 2005;49:3317–24.PubMedCrossRef

50.

Hope WW, Seibel NL, Schwartz CL, et al. Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. Antimicrob Agents Chemother. 2007;51:3714–9.PubMedCrossRef

51.

Heresi GP, Gerstmann DR, Reed MD, et al. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis J. 2006;25:1110–5.PubMedCrossRef

52.

Hope WW, Mickiene D, Petraitis V, et al. The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. J Infect Dis. 2008;197:163–71.PubMedCrossRef

53.

• Hope WW, Smith PB, Arrieta A, et al. Population pharmacokinetics of micafungin in neonates and young infants. Antimicrob Agents Chemother. 2010;54:2633–7. The results of this important study suggest the need for higher doses of micafungin in premature neonates.PubMedCrossRef

54.

Smith PB, Walsh TJ, Hope W, et al. Pharmacokinetics of an elevated dosage of micafungin in premature neonates. Pediatr Infect Dis J. 2009;28:412–5.PubMedCrossRef

55.

• Queiroz-Telles F, Berezin E, Leverger G, et al. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Pediatr Infect Dis J. 2008;27:820–6. This pediatric substudy, as part of a double-blind, randomized, multinational trial, included 106 children to compare micafungin (2 mg/kg) with liposomal amphotericin B (3 mg/kg) as first-line treatment of invasive candidiasis.PubMedCrossRef

56.

Arrieta A, Maddison P, Groll AH. Micafungin in pediatric patients: assessment of safety in clinical trials [abstract], 2007. Presented at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL; September 17–20, 2007: M-1162.

57.

Mycamine Summary of Product Characterization. Available at http://www.emea.europa.eu/humandocs/humans/EPAR/mycamine/mycamine.htm. Accessed January 10, 2011.

Title: Antifungal Therapy in Pediatric Patients
Authors: Thomas Lehrnbecher
Konrad Bochennek
Dominik Schrey
Andreas H. Groll
Publication date: 01-06-2011
Publisher: Current Science Inc.
Published in: Current Fungal Infection Reports / Issue 2/2011
Print ISSN: 1936-3761
Electronic ISSN: 1936-377X
DOI: https://doi.org/10.1007/s12281-011-0046-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2011

Antifungal Pharmacokinetics and Dosing Considerations in Burn Patients

Update on Antifungal Drug Dosing and Therapeutic Drug Monitoring

Pros and Cons of Extrapolating Animal Data on Antifungal Pharmacodynamics to Humans

Optimizing Amphotericin B Therapy for Cryptococcal Meningitis

Antifungal Dosing in Obesity: A Review of the Literature

Antifungal Dosing in Dialysis and Continuous Renal Replacement Therapy

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials